Astrana Health (ASTH) Stock Forecast & Price Target

Compare

267 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ASTH Analyst Ratings

Strong Buy

6 Buy

2 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Astrana

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ASTH Stock 12 Month Forecast

Average Price Target

$31.50

▲(35.72% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Astrana Health in the last 3 months. The average price target is $31.50 with a high forecast of $37.00 and a low forecast of $26.00. The average price target represents a 35.72% change from the last price of $23.21.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"$20","45":"$45","26.25":"$26.3","32.5":"$32.5","38.75":"$38.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$37.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,26.25,32.5,38.75,45],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.18,24.243076923076924,25.306153846153848,26.369230769230768,27.432307692307692,28.495384615384616,29.558461538461536,30.62153846153846,31.684615384615384,32.747692307692304,33.81076923076923,34.87384615384615,35.93692307692308,{"y":37,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.18,23.82,24.46,25.1,25.74,26.38,27.02,27.66,28.3,28.939999999999998,29.58,30.22,30.86,{"y":31.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.18,23.396923076923077,23.613846153846154,23.83076923076923,24.04769230769231,24.264615384615386,24.481538461538463,24.698461538461537,24.915384615384614,25.13230769230769,25.34923076923077,25.566153846153846,25.783076923076923,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":44.81,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.87,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.38,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.86,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.06,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.57,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.88,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.21,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$37.00

Average Price Target$31.50

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Jailendra Singh

Truist Financial

Buy

―

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN), Astrana Health (NASDAQ: ASTH) and Gilead Sciences (NASDAQ: GILD)

Matthew Shea

Needham

$28

Buy

20.64%

Upside

Initiated

12/12/25

Astrana Health Positioned for Aggressive Growth and Valuation Upside Amidst Strong Financials and Market Opportunities

Jack Slevin

Jefferies

$44→$37

Buy

59.41%

Upside

Reiterated

11/25/25

Astrana Health price target lowered to $37 from $44 at JefferiesAstrana Health price target lowered to $37 from $44 at Jefferies

Andrew Mok CFA

Barclays

$36→$26

Hold

12.02%

Upside

Reiterated

11/21/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Astrana Health (NASDAQ: ASTH) and Bristol-Myers Squibb (NYSE: BMY)

Matthew Gillmor CFA

KeyBanc

Hold

―

Reiterated

11/10/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Astrana Health (NASDAQ: ASTH) and Roche Holding AG (Other OTC: RHHVF)

Ryan Langston

TD Cowen

$40→$35

Buy

50.80%

Upside

Reiterated

11/10/25

Analysts Conflicted on These Healthcare Names: Alector (NASDAQ: ALEC), Arcellx Inc (NASDAQ: ACLX) and Astrana Health (NASDAQ: ASTH)

Michael Craig Jones

Bank of America Securities

Buy

―

Reiterated

11/07/25

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH), Astrana Health (NASDAQ: ASTH) and Progyny (NASDAQ: PGNY)

Ryan Daniels

William Blair

Buy

―

Reiterated

11/07/25

Strong Q3 Performance and Strategic Partnerships Justify Buy Rating for Astrana Health

Michael Ha

Robert W. Baird

$48

Buy

106.81%

Upside

Reiterated

08/14/25

David Larsen

BTIG

$50

Buy

115.42%

Upside

Reiterated

08/10/25

Astrana Health: Strong Financial Performance and Strategic Growth Drive Buy Rating

Brooks O'Neil

Lake Street

$70

Buy

201.59%

Upside

Reiterated

05/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioHarvest Sciences (NASDAQ: BHST), Astrana Health (NASDAQ: ASTH) and Joint (NASDAQ: JYNT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Jailendra Singh

Truist Financial

Buy

―

Reiterated

12/15/25

Analysts Offer Insights on Healthcare Companies: Novan (NASDAQ: NOVN), Astrana Health (NASDAQ: ASTH) and Gilead Sciences (NASDAQ: GILD)

Matthew Shea

Needham

$28

Buy

20.64%

Upside

Initiated

12/12/25

Astrana Health Positioned for Aggressive Growth and Valuation Upside Amidst Strong Financials and Market Opportunities

Jack Slevin

Jefferies

$44→$37

Buy

59.41%

Upside

Reiterated

11/25/25

Astrana Health price target lowered to $37 from $44 at JefferiesAstrana Health price target lowered to $37 from $44 at Jefferies

Andrew Mok CFA

Barclays

$36→$26

Hold

12.02%

Upside

Reiterated

11/21/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Insulet (NASDAQ: PODD), Astrana Health (NASDAQ: ASTH) and Bristol-Myers Squibb (NYSE: BMY)

Matthew Gillmor CFA

KeyBanc

Hold

―

Reiterated

11/10/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Astrana Health (NASDAQ: ASTH) and Roche Holding AG (Other OTC: RHHVF)

Ryan Langston

TD Cowen

$40→$35

Buy

50.80%

Upside

Reiterated

11/10/25

Analysts Conflicted on These Healthcare Names: Alector (NASDAQ: ALEC), Arcellx Inc (NASDAQ: ACLX) and Astrana Health (NASDAQ: ASTH)

Michael Craig Jones

Bank of America Securities

Buy

―

Reiterated

11/07/25

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (NASDAQ: AMPH), Astrana Health (NASDAQ: ASTH) and Progyny (NASDAQ: PGNY)

Ryan Daniels

William Blair

Buy

―

Reiterated

11/07/25

Strong Q3 Performance and Strategic Partnerships Justify Buy Rating for Astrana Health

Michael Ha

Robert W. Baird

$48

Buy

106.81%

Upside

Reiterated

08/14/25

David Larsen

BTIG

$50

Buy

115.42%

Upside

Reiterated

08/10/25

Astrana Health: Strong Financial Performance and Strategic Growth Drive Buy Rating

Brooks O'Neil

Lake Street

$70

Buy

201.59%

Upside

Reiterated

05/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioHarvest Sciences (NASDAQ: BHST), Astrana Health (NASDAQ: ASTH) and Joint (NASDAQ: JYNT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Astrana Health

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+5.57%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.57% per trade.

3 Months

xxx

Success Rate

6/9 ratings generated profit

Average Return

+0.21%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +0.21% per trade.

1 Year

David LarsenBTIG

Success Rate

3/9 ratings generated profit

Average Return

-0.68%

reiterated a buy rating 4 months ago

Copying David Larsen's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -0.68% per trade.

2 Years

xxx

Success Rate

1/11 ratings generated profit

Average Return

-29.07%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 9.09% of your transactions generating a profit, with an average return of -29.07% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ASTH Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ASTH has received 10 Buy Ratings, 6 Hold Ratings, and 0 Sell Ratings. ASTH average Analyst price target in the past 3 months is 31.50.

Each month's total comprises the sum of three months' worth of ratings.

ASTH Financial Forecast

ASTH Earnings Forecast

Next quarter’s earnings estimate for ASTH is $0.09 with a range of -$0.01 to $0.17. The previous quarter’s EPS was $0.01. ASTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ASTH has Performed in-line its overall industry.

ASTH Sales Forecast

Next quarter’s sales forecast for ASTH is $930.44M with a range of $903.75M to $953.54M. The previous quarter’s sales results were $956.05M. ASTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ASTH has Performed in-line its overall industry.

ASTH Stock Forecast FAQ

What is ASTH’s average 12-month price target, according to analysts?

Based on analyst ratings, Astrana Health’s 12-month average price target is 31.50.

What is ASTH’s upside potential, based on the analysts’ average price target?

Astrana Health has 35.72% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ASTH a Buy, Sell or Hold?

Astrana Health has a consensus rating of Strong Buy which is based on 6 buy ratings, 2 hold ratings and 0 sell ratings.

What is Astrana Health’s price target?

The average price target for Astrana Health is 31.50. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $37.00 ,the lowest forecast is $26.00. The average price target represents 35.72% Increase from the current price of $23.21.

What do analysts say about Astrana Health?

Astrana Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ASTH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Astrana Health (ASTH) Stock Forecast & Price Target

ASTH Analyst Ratings

ASTH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Astrana Health

ASTH Analyst Recommendation Trends

ASTH Financial Forecast

ASTH Earnings Forecast

ASTH Sales Forecast

ASTH Stock Forecast FAQ

Detailed List of Analyst Forecasts